Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · France
Declared costs: €100K+ a year · in the register since 2012
Industry association · Belgium
Declared costs: €1.5M+ a year · in the register since 2008
Medicinal products for human use · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
American Chamber of Commerce to the EU · filed 27 Apr 2021 · source
The American Chamber of Commerce to the EU (AmCham EU) is committed to the development of a regulatory environment which furthers the capabilities of European healthcare, improving accessibility and ensuring a crisis-resistant medicines regulatory system.
Ipsen Pharma · filed 6 Nov 2023 · source
Ipsen, a global biopharmaceutical company committed to improving patients' lives through breakthrough innovations, focuses on unmet medical needs, particularly in oncology, rare diseases and neuroscience. We support the objectives of the reform but urge more ambition to foster innovation for people with rare diseases and improve Europes competitiveness and attractiveness.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
Ipsen Pharma · filed 6 Jan 2021 · source
As a global specialty-driven biopharmaceutical company committed to discovering new solutions for debilitating rare and ultra-rare diseases and improving quality of life for patients suffering from these diseases, Ipsen welcomes the opportunity to comment on the inception impact assessment.
American Chamber of Commerce to the EU · filed 6 Jan 2021 · source
Representing American companies operating in the EU, AmCham EU is well aware of the differences and respective strengths of innovation ecosystems on both sides of the Atlantic. The options laid out in the inception impact assessment (IIA) risk undermining an EU framework that has proven largely successful, rather than preserving the EU’s strengths and incorporating learnings from other regions.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.